Department of Hematology and Oncology, Beilun District People's Hospital, Ningbo, 315800, China.
Department of Hematology and Oncology, Beilun Branch of the First Affiliated Hospital of Zhejiang University, Ningbo, 315800, China.
Breast Cancer Res. 2024 Sep 20;26(1):137. doi: 10.1186/s13058-024-01895-6.
Breast cancer is the most common malignant tumor among women worldwide and remains one of the leading causes of death among women. Its incidence and mortality rates are continuously rising. In recent years, with the rapid advancement of deep learning (DL) technology, DL has demonstrated significant potential in breast cancer diagnosis, prognosis evaluation, and treatment response prediction. This paper reviews relevant research progress and applies DL models to image enhancement, segmentation, and classification based on large-scale datasets from TCGA and multiple centers. We employed foundational models such as ResNet50, Transformer, and Hover-net to investigate the performance of DL models in breast cancer diagnosis, treatment, and prognosis prediction. The results indicate that DL techniques have significantly improved diagnostic accuracy and efficiency, particularly in predicting breast cancer metastasis and clinical prognosis. Furthermore, the study emphasizes the crucial role of robust databases in developing highly generalizable models. Future research will focus on addressing challenges related to data management, model interpretability, and regulatory compliance, ultimately aiming to provide more precise clinical treatment and prognostic evaluation programs for breast cancer patients.
乳腺癌是全球女性中最常见的恶性肿瘤,仍然是女性死亡的主要原因之一。其发病率和死亡率持续上升。近年来,随着深度学习(DL)技术的快速发展,DL 在乳腺癌诊断、预后评估和治疗反应预测方面显示出了巨大的潜力。本文综述了相关研究进展,并应用 DL 模型对 TCGA 和多个中心的大型数据集进行图像增强、分割和分类。我们使用了 ResNet50、Transformer 和 Hover-net 等基础模型,研究了 DL 模型在乳腺癌诊断、治疗和预后预测中的性能。结果表明,DL 技术显著提高了诊断的准确性和效率,特别是在预测乳腺癌转移和临床预后方面。此外,该研究强调了稳健数据库在开发高度通用模型中的关键作用。未来的研究将集中解决与数据管理、模型可解释性和法规遵从性相关的挑战,最终旨在为乳腺癌患者提供更精确的临床治疗和预后评估方案。
Breast Cancer Res. 2024-9-20
Semin Cancer Biol. 2021-7
IEEE J Biomed Health Inform. 2018-12-5
Sci Rep. 2021-12-21
Front Pharmacol. 2025-8-20
Mayo Clin Proc Digit Health. 2025-7-18
Diagnostics (Basel). 2025-7-1
Epigenetics Chromatin. 2025-6-14
Genome Med. 2024-3-27
J Hematol Oncol. 2023-11-27
Trends Cancer. 2024-2
Int J Mol Sci. 2023-10-10
BMC Bioinformatics. 2023-10-26